<u id="zkwwc"><dd id="zkwwc"></dd></u>

<sub id="zkwwc"></sub>
<dd id="zkwwc"></dd><nav id="zkwwc"></nav>

        Continued strong sales growth in the first half, ahead of underlying market rates

        June 2018
        • Revenue growth of 9.8% (11.2% constant currency1)
        • Full year constant currency revenue growth guidance increased to c.11%, including the impact of the Spring Bioscience licence agreement signed in January 2018

        FINANCIAL HIGHLIGHTS

        • Total revenue growth of 9.8% on a reported basis to £112.5m (H1 2017:? £102.5m) and 11.2% on a constant currency basis
        • Catalogue revenue growth of 10.0% on a reported basis to £105.2m (H1 2017: £95.6m) and 11.5% on a constant currency basis
          • Recombinant antibody revenues grew by 21.1% to £22.4m on a reported basis and by 22.8% on a constant currency basis
          • Immunoassay product revenues grew by 20.7% to £7.0m on a reported basis and by 23.4% on a constant currency basis
        • Reported gross margin broadly in line with last year at 69.8% (H1 2017: 69.7%)
        • EBITDA margin was 34.7% (H1 2017: 34.5%). Adjusted EBITDA margin2 increased to 38.0% (H1 2017: 35.1%), primarily as a result of the rolling-off of hedging contracts in the prior period
        • Profit before tax (PBT) on a reported basis was £32.8m (H1 2017: £25.1m) and £39.3m (H1 2017: £32.1m) on an adjusted basis
        • Reported diluted earnings per share (EPS) increased 61.9% to 15.7 pence (H1 2017: 9.7 pence). Adjusted2 diluted EPS increased by 20.2% to 15.5 pence (H1 2017: 12.9 pence)
        • Interim dividend increased by 21.1% to 3.42 pence (H1 2017: 2.825 pence)

        ?OPERATIONAL HIGHLIGHTS

        • Continued commercial and strategic execution in the period, with all regions growing above underlying market rates and the achievement of all strategic key performance targets
        • Exclusive licence agreement announced with Roche in January 2018, covering approximately 760 Spring Bioscience products, including 243 rabbit monoclonal antibodies, in research use only (RUO) applications
        • FirePlex? (formerly Firefly) platform expanded within the kits/assays range by introducing 47 new antibody pairs and validated many of these pairs in multiplex immunoassays
        • Further increased our addressable market in custom products and licensing, with twenty pharmaceutical and diagnostic partners signed up to ‘Abcam Inside’ framework agreements over the last 24 months
        • Made continued progress towards full implementation of our new Oracle Cloud ERP system, although we no longer expect to go live in this financial year
        • Construction of our new headquarters in Cambridge on plan and we anticipate moving in early 2019

        Commenting on the interim results, Alan Hirzel, Abcam’s Chief Executive Officer, said:

        “It has been another good half for Abcam, delivering double digit revenue growth whilst meeting all of our financial and strategic targets. Our cash generation and balance sheet strength underpin continued investment into our teams, our systems and our facilities to enable us to grow. We remain on track to meet our strategic goals for the year and we have increased our revenue guidance for the full year. This momentum positions us well to deliver on our long-term goals, which we anticipate will continue to drive sustainable value for our shareholders.”

        1. Constant currency results are calculated by applying prior period’s actual exchange rates to this period’s results.
        2. Adjusted results exclude the effects of system and process improvement costs (including related impairments), contingent consideration fair value adjustments, acquisition costs, the amortisation of acquisition related intangible assets, related tax effects and significant one-off tax items. Such excluded items are described as “adjusting items”. For further details, see note 4 to the interim financial information.

        For further information please contact

        Abcam + 44 (0) 1223 696 000
        Alan Hirzel, Chief Executive Officer

        Gavin Wood, Chief Financial Officer

        James Staveley, Vice President, Investor Relations

        J.P. Morgan Cazenove – Nominated Advisor & Corporate Broker + 44 (0) 20 7742 4000
        James Mitford / Candelle Chong
        FTI Consulting +44 (0) 20 3727 1000
        Ben Atwell / Brett Pollard / Natalie Garland-Collins

         

        Link to full release:?https://otp.investis.com/clients/uk/abcamplc/rns/regulatory-story.aspx?cid=128&newsid=984559

        About Abcam

        Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

        Read more +

        Abcam Products

        As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

        Read more +

        Investor Information

        Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

        Read more +

        Abcam News

        We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

        Read more +
        国产A片